Ranbaxy gets USFDAs permission to manufacture cardiovascular drugs
March 9th, 2009 - 4:41 pm ICT by ANIMumbai, Mar. 9 (ANI): Drug-maker Ranbaxy Laboratories has got approval from the US Federal Drug Administration to market and manufacture Ramipril, which is used in the treatment of cardiovascular diseases. The pharmaceuticals company has received final nod from US Food and Drug Administration (US FDA) for Ramipril capsules, it said in a filing to the Bombay Stock Exchange. Ranbaxy is pleased to receive this final approval for Ramipril capsules. This is the third Abbreviated New Dug Application (ANDA) approval that materialised specific to Ohm Laboratories, in the last two months, Ranbaxy Pharmaceuticals Inc VP (Sales and Distribution) Jim Meehan said. Ramipril is a bio-equivalent to King Pharmaceuticals” Altace drug, which can be used to treat hypertension. The drug will be available in the strength of 5mg and 10mg capsules. Ranbaxys US-based subsidiary Ohm Laboratories” facility at New Jersey filed the application for the drug manufacturing permission. Shares of Ranbaxy were trading at 139.70 rupees, down 1.13 percent on the Bombay Stock Exchange. (ANI)
- Ranbaxy approved to make first generic version of Lipitor - Dec 01, 2011
- Orchid gets tentative FDA approval for Alzheimer's drug - Jan 08, 2010
- Ranbaxy ordered to improve India, US plants - Jan 26, 2012
- Dr Reddy's launches anti-asthma tablets in US - Nov 20, 2010
- Ranbaxy boosts presence in Africa with malaria drug - May 11, 2012
- Dr Reddy's to launch lansoprazole capsules in US - Oct 16, 2010
- Ranbaxy to launch anti-diabetic drug Actos by 2012 - Mar 15, 2010
- Sun Pharma gets US nod for leukaemia drug - Nov 17, 2009
- Natco Pharma launches anti-swine flu medicine (Business Capsule) - Sep 18, 2009
- Ranbaxy Q3 2010 profit up 168 percent - Nov 11, 2010
- Sun Pharma gets US approval for Paraplatin injection - Sep 23, 2008
- Daiichi, Ranbaxy to cooperate with US drug regulator as Indian firm faces charge (Lead) - Feb 26, 2009
- Decks cleared for Orchid to market anti-infectives in US - Sep 25, 2009
- Lupin buys anti-cholesterol drug rights for $39 mn - Sep 29, 2009
- Ranbaxy's South African arm bags $133 million order - Dec 20, 2010
Tags: altace, bombay stock exchange, cardiovascular diseases, cardiovascular drugs, fda, federal drug administration, final approval, food and drug, food and drug administration, hypertension, jim meehan, king pharmaceuticals, last two months, nod, pharmaceuticals company, pharmaceuticals inc, ramipril, ranbaxy laboratories, rupees, vp sales